Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

56.41 +0.75 (+1.35%)
Official Closing Price Updated: 4:15 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,190,568
Open 55.93
Bid (Size) 56.41 (1)
Ask (Size) 57.25 (1)
Prev. Close 55.66
Today's Range 55.56 - 58.67
52wk Range 37.55 - 91.10
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex is broadening its portfolio. 
Via The Motley Fool
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
Via The Motley Fool

Performance

YTD
-14.61%
-14.61%
1 Month
-20.64%
-20.64%
3 Month
-14.78%
-14.78%
6 Month
+35.89%
+35.89%
1 Year
+10.43%
+10.43%

More News

Read More
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Via The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
Via Benzinga
Is It Too Late to Buy CRISPR Therapeutics Stock?
Via The Motley Fool
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
Via The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
Via The Motley Fool
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Via InvestorPlace
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000
Via The Motley Fool
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Via The Motley Fool
3 Stocks That Could Be the Next Big Thing in Gene Editing
Via InvestorPlace
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Via MarketBeat
Exposures Product Safety
The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024
Via InvestorPlace
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
Via Benzinga
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Via Talk Markets
The Top 3 Biotech Stocks to Buy in March 2024
Via InvestorPlace
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Via MarketBeat
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
Via The Motley Fool
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
MarketBeat Week in Review – 2/26 - 3/1
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.